Hepatocellular carcinoma (HCC) is the most frequent type of malignant liver tumor in Thailand. The high incidence rate of HCC reflects from chronic HBV infection in this endemic area. Some patients are asymptomatic at presentation whereas many of them presented at advanced stage of HCC with limited treatment options and grave outcome. The Barcelona Clinic Liver Cancer (BCLC) staging system and management allocation for HCC is widely accepted and used in many international guidelines including Thailand. Curative treatment is expected in early stage of HCC while palliative treatment, combination treatment and best supportive care are offered to advanced stage of HCC. The most effective strategy to prevent the development of HCC is prevention of HBV vertical transmission and treatment HBV or HCV infection. The purpose of this article is to update information of HCC in Thailand including epidemiology, diagnosis, clinical manifestation, and treatment.
Introduction
Hepatocellular carcinoma (HCC) is one of the world common malignant tumors. It accounts as the sixth most common cancer, and the second global cancer related death (1) . The well-established common risk factors for developing HCC are cirrhosis from any causes. The clinical presentation of HCC depends on the stage of diagnosis and liver function status. Patients usually presented with advanced stage of HCC and cirrhosis because of unawareness of their own risks. Hepatic resection, liver transplantation and radiofrequency ablation are the choices of curative treatment for HCC. To reduce of HCC development, prevention of HBV vertical transmission and treating chronic HBV/HCV infection are the effective strategy to halt the progression of chronic liver disease, cirrhosis and HCC.
Epidemiology
According to GLOBOSCAN 2012, the incidence of HCC is the sixth most common cancer in the world. The highest incidence countries (>10 per 100 000/year) are observed in China, Southeast Asia including Thailand, sub-Saharan western and eastern Africa (1) . In Thailand, the age-standardized incidence rate of HCC in both sexes is 22.3 per 100,000/year whereas the age-standardized incidence rates are 34.8 per 100 000/year and 11.3 per 100 000/year in men and in women, respectively.
The common risk factors of HCC are chronic HBV infection, chronic HCV infection and alcohol consumption (2) (3) (4) (5) . Recent report of Thai patients with HCC in 2014 confirmed chronic HBV infection was the most common risk factor of HCC (5) . Chronic HBV infection accounted 49.8% of the total HCC patients followed by alcohol consumption, chronic HCV infection and cryptogenic cirrhosis. Interestingly, all non-cirrhotic patients with HCC (nine cases, 7.2% of total HCC cases) had chronic HBV infection. This chronic HBV infection as the major risk factor of developing HCC was subsequently studied (6) . The mean age of chronic HBV infection patients with HCC were older than those without HCC. Complications of cirrhosis were also more common in chronic HBV infection patients with HCC than those without HCC. These findings supported the correlation of chronic HBV infection with cirrhosis and HCC in previous report from other Asian countries.
The mortality rate of HCC is the second most common cause of cancer death in the world (1) . In Thailand, the age-standardized mortality rate of HCC is 21.5 per 100 000/year. The agestandardized mortality rates are 33.1 per 100 000/year and 11.3 per 100 000/year in men and women, respectively.
Diagnosis and staging
The diagnosis of HCC is commonly dependent on the diagnostic criteria used by either the American Association Study of Liver Disease (AASLD) (7) or Asia Pacific Association for the Study of the liver (APASL) (8) . Recently, Thai Association of the Study of the Liver (THASL) has developed 2015 Thailand guideline for management of HCC. This guideline is electronically distributed to Thai physicians at www.thasl.org/th/academic.php. The ultrasonography of abdomen is the first line investigation for surveillance in Thailand due to low cost, non-invasive and good information. Anyone who have suspected nodule(s) by ultrasonography will be proceed to investigate by either a dynamic CT or MRI (with liver specific contrast) to diagnose HCC while liver biopsy is indicated for unresolved diagnosis by imaging studies.
The Barcelona Clinic Liver Cancer (BCLC) staging system and treatment allocation for HCC is used to determine to stage of disease and the choice of treatment.
Clinical presentation
The presentation of HCC depends on the stage of disease and underlying liver status. Patients who have risk of developing HCC and are in HCC surveillance program would be diagnosed at the early stage of HCC without any symptoms. On the contrary, patients (with or without known risk) who have never seek medical treatment always present either in the advanced stage of HCC or complication of cirrhosis.
In terms of clinical characteristic of patients in Thailand, recent report in 2014 by Somboon et al. (5) revealed the mean age of HCC diagnosis was~57 years with male predominance (79%). The common presentation was hepatomegaly (51%) followed by abdominal discomfort (45%) and ascites (21%). An asymptomatic patient at the time of diagnosis was 25%. Cirrhosis was the common associated disease (93%). The BCLC staging system of HCC was as follows: stage 0 9%, stage A 16%, stage B 38%, stage C 11% and stage D 26%. During the course of disease, one-third of HCC patients developed at least one complication. Spontaneous rupture of HCC was the most common complication followed by spontaneous bacterial peritonitis, septicemia and variceal bleeding.
Treatment
Modes of treatment are dependent on stage of disease, liver status, physical status, financial issue and the level of health care center. In general, patients with single, small lesion in liver without cirrhosis are the good candidate for curative treatment by resection. Whereas multiple lesions with or without cirrhosis might be aimed for curative with liver transplantation or radiofrequency ablation (RFA).
Patients with large tumor size, portal vein invasion, evidence of metastasis, Child-Pugh C and poor physical status are offered to palliative care, for example, transarterial chemoembolization (TACE), sorafenib and symptomatic treatment (9) . Currently, all international HCC management guidelines including Thailand refer to the staging and treatment allocation by the BCLC (7, 8, 10) . TACE is the most common mode of treatment in Thailand because of advanced stage, available health center and acceptable cost of treatment (US$500-1500) (2, 3, 5, 11) .
Hepatic resection and liver transplantation are important curative treatment for HCC. A single lesion easily accessible by surgical technique and expected adequate liver volume would be offered surgical resection, while liver transplantation is the treatment for cirrhotic patients with HCC. This treatment decision would be discussed within multidisciplinary team in each centers. Because of the heterogeneity of HCC, liver status, surgical expertise and level of health care center, the national treatment outcome of hepatic resection in Thailand has not been well organized, collected and published. According to the BCLC treatment, evidences support the survival benefit for patients who were within the Milan criteria. Single lesion with less than 5 cm or three lesions with each less than 3 cm without vascular invasion and metastasis showed promising result with liver transplantation (12, 13) . However, the main obstacle of liver transplantation is limited numbers of donor because of the cultural belief in Thai population. According to Thai red cross organ donation center annual report in 2015 (http:// en.organdonate.in.th), the number of liver transplantation in the last 3 years was 71, 76 and 73 cases in 2015, 2014 and 2013, respectively. A case series report about liver transplantation by a single university hospital in Thailand during 2002-13 found HCC was the most common indication for orthotopic liver transplantation (14) . Forty-eight percent of 120 adult orthotopic liver transplantation were HCC. The 1-and 5-year survival were 85% and 69%, respectively.
RFA is a major choice of curative treatment for patients who are not eligible to undergo surgical resection or liver transplantation. A recent study of RFA by Siriapisith et al. showed a local response rate in RFA was 97.3% with a 6.9% recurrent rate during 283.2 ± 176.6 days of follow-up time. The complication rate was 0.07% and all of these were minor complication (15) .
TACE is the most common mode of treatment in Thailand due to advanced stage of HCC (2, 3, 5, 11) . This treatment was offered for patients with HCC intermediate stage (BCLC stage B). It was accounted 13-41.6% of total treatment for HCC. The median survival of patient with HCC after TACE treatment is 6.3-11.5 months. Fever and right upper quadrant pain are common complication of TACE treatment.
Many evidences supported combination treatment improved treatment outcome of patients who were not suitable for single treatment. TACE followed by surgical resection showed much more median survival than TACE alone (16.27 months vs 8.38 months) (2). Additionally, an evidence supported RFA combined with TACE is an alternative treatment option for controlling local tumor in liver size larger than 3 cm. Median survival times were 24 months in the TACE group, 22 months in the RFA group, and 37 months in the TACE-RFA group during a median 28.5 months of follow-up (16) . Tumor size larger than 3 cm, infiltrative tumors, and previous treatment were the risk factor of local tumor progression after RFA combined with TACE (17) .
Sorafenib have been approved for systemic treatment in advanced stage of HCC (BCLC stage C), well-preserved liver function and unsuitable for loco-regional treatment (7). Many evidences support several months survival benefit of sorefenib in advanced stage of HCC (18, 19) . FOLFOX4 regimen is another choice for palliative systemic therapy for advanced stage HCC. Qin et al. reported the study of FOLFOX4 regimen for advanced HCC patients in Asian countries included China, Taiwan, Korea and Thailand (20) . Although this study did not show overall survival benefit of FOLFOX4 regimen, the trend seemed toward improvement in overall survival with FOLFOX4 regimen. This regimen would be the alternative regimen for patients whom not suitable for other choices of treatment.
Best supportive care is a good option for patients with terminal stage. Health care providers have to deal with the progression of disease itself, deterioration of liver function, portal hypertension related complication and psychological problems in terminal illness patients. Psychological support is a very important issue for caring patients with terminal disease. Once disease progresses to terminal stage, almost all patients would develop hepatic encephalopathy resulting in drowsiness, semi-coma or coma. Family therapy is needed to understand the goal of treatment and aware of the end of patient's life.
Prevention
Prevention of HCC is an important aspect for anyone who has chronic liver disease. Regarding that the most common risk factors for HCC in Thailand are chronic HBV infection, the national HBV vaccination program for all newborns that has been implemented since 1991 is the most effective way to prevent vertical transmission. The prevalence rate of HBV infection has been decreasing significantly from 7.8% in 1988 to 2.6% in 2009 (21) . Asia-Pacific consensus statements on management of chronic HBV and HCV infection has been implemented since 2000 (22) . The current version of this management guideline has been published in January 2016 (23) . For those who have chronic HBV infection with high risk of HCC, treatment is given either antiviral agent or interferon. Lamivudine is the preferred choice of treatment for almost all patients because of economic status. Once patients developed drug resistance to lamivudine, it will be replaced by tenofovir.
In term of patients with chronic HCV infection, treatment was initiated following the guideline since 2000 (22). Patients with risks of HCV-related liver complication are the first priority of free of charge treatment under Thailand government policy in recent years. These regimens are the combination of pegylated interferon alpha and ribavirin for a duration of 24 weeks for genotype 2 or 3 and a duration of 48 weeks for other genotypes. The current 2016 AsiaPacific management guideline for HCV infection recommends either traditional treatment with pegylated interferon alpha plus ribavirin and direct-acting antiviral (DAA) (24) . New oral direct antiviral therapy for HCV infection shows an excellent result in almost all patients (the sustained virological response rate after 12 weeks of treatment end, SVR 12, >95%) but the cost of treatment is hardly affordable for Thai patients.
With the effectiveness of either prevention of HBV vertical transmission program and HBV/HCV treatment in high risk group, the age-standardized incidence rate of HCC in Thailand trends to decrease in the last decade (1992-2012) (1,25). The age-standardized incidence rate in men was 37.4 per 100 000/year in 1992 and 34.8 per 100 000/year in 2012. The age-standardized incidence rate in women was 16.3 per 100 000/year in 1992 and 11.3 per 100 000/year in 2012. The trend of patients diagnosed with HCC seems to be decreasing over 10 years with HCC prevention strategy. The HCC incidence rate report in the next decade is needed to prove the effectiveness of HCC prevention.
Conclusion
HCC is one of the most common cancers in Southeast Asian countries including Thailand. A half of patients have chronic HBV infection as a risk factor of HCC. Cirrhosis is a common underlying disease in patient with HCC. Patients with advanced stage of HCC at the presentation is common and have poor treatment outcome.
Prevention of developing HCC by prevention of HBV vertical transmission and controlling HBV/HCV infection are the effective strategy to reduce the burden of disease in the world and Thailand.
